Trigonelline reduced diabetic nephropathy and insulin resistance in type 2 diabetic rats through peroxisome proliferator-activated receptor-γ

YINYAN LI¹, QAOBEI LI¹, CHUNYAN WANG¹, ZHE LOU¹ and QINGCHANG LI²

Departments of ¹Ultrasonic Diagnosis and ²Pathology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China

Received February 11, 2018; Accepted June 15, 2018

DOI: 10.3892/etm.2019.7698

Abstract. Trigonelline has been reported to serve an important role in cell cycle control, oxidative and ultraviolet stress and DNA methylation. In the present study, the effects of trigonelline were examined on type-2 diabetes mellitus (T2DM)-induced renal dysfunction, and its possible mechanism was investigated. Sprague-Dawley rats were fed with high-fat diet (HFD) for 4 weeks and intraperitoneally injected with 35 mg/kg of streptozotocin for 4 weeks. As a result, trigonelline increased body weight, inhibited the kidney weight/body weight ratio and blood glucose levels, and reduced the levels of blood urea nitrogen, creatinine and albumin in type 2 diabetic rats. In addition, trigonelline also reduced inflammation, oxidative stress and kidney cell apoptosis in T2DM rats. In terms of the molecular mechanisms involved, trigonelline induced the protein expression of peroxisome proliferator-activated receptor (PPAR)−γ and suppressed glucose transporter 4 but suppressed the protein expression of tumor necrosis factor-α and leptin in T2DM rats. The present results demonstrated that trigonelline reduced diabetic nephropathy and insulin resistance in T2DM rats through PPAR-γ.

Introduction

According to Chinese epidemiological studies in 2012, the morbidity of chronic kidney disease (CKD) in China is 10.0% and ~36.4% of the population have been diagnosed with diabetes (1). Research indicates that diabetes is an independent risk factor of CKD (1). According to the World Health Organization evaluation data, the population in China includes a total of 0.114 billion diabetics and 0.493 pre-diabetics (2). Importantly, the diabetic population is estimated to increase to 0.13 billion by 2025 (2). Diabetic nephropathy (DN) is a major complication of diabetes, which is also a leading cause of end-stage renal disease (ESRD) and dialysis in Western countries (3). The national dialysis registration quality control data (2012) in China indicate that 18.4% of new hemodialysis patients have DN. Furthermore, a total of 17.5% of the new peritoneal dialysis patients have DN. Notably, DN has become the second leading cause of ESRD and dialysis in China (3).

Numerous clinical studies have indicated that peroxisome proliferator-activated receptor (PPAR)-γ receptor agonist has favorable renal protective effects (4). PPAR-γ is extensively applied during the treatment of diabetes. Notably, PPARs are nuclear hormone receptor superfamily members (5) and nuclear transcription factors, which are activated by ligands. There are three major subtypes, namely, α, β and γ. Evidence indicates that PPAR-γ is widely expressed in glomerulus, renal proximal convoluted tubule, renal fibroblast and renal collecting tubule (6). Furthermore, research on the role of PPAR-γ in DN has attracted much attention in previous years (6).

Trigonelline is a major alkaloid isolated from the dry seed of Trigonella foenum-graecum L (7). It has been demonstrated to possess hypoglycemic, cholesterol-lowering, neural regeneration-promoting, anticancer and sedation effects (8). Notably, trigonelline can suppress β-amyloid protein in a dose-dependent manner (9). Furthermore, trigonelline has been demonstrated to induce neuron dendrite and axon atrophy, promote cerebral cortical neuron dendrite and axon regeneration (9), therefore protecting the central nervous system neuron (8). Zhou et al (8) suggested that trigonelline inhibits inflammation to prevent fetal growth restriction during pregnancy in diabetes. Furthermore, Ghule et al (10) indicated that trigonelline ameliorates diabetic hypertensive nephropathy. These findings suggest that trigonelline may be able to protect the central nervous system neurons.

Materials and methods

Experimental animals and induction of diabetes in rats. A total of 22 male Sprague-Dawley rats aged 5-6 weeks old
(150-170 g) were housed in a temperature-controlled environment (temperature, 22-22°C; humidity, 55-5%) with a 12-h light/dark cycle and ad libitum access to food and water. All rats were randomly divided into three groups: Control (n=6), type 2 diabetes mellitus (T2DM) model (n=8) and trigonelline (n=8) groups. In T2DM model or trigonelline groups, rats were induced with T2DM. T2DM was induced in rats by feeding a high-fat diet (HFD, TP 28708, Trophi Feed High-tech Co., Ltd., Nantong, China) for 4 weeks. The T2DM model was confirmed when serum glucose were >16.7 mM. Subsequently, rats were intraperitoneally injected with 35 mg/kg of streptozotocin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 4 weeks and were also fed a HFD during these additional 4 weeks. In the control group, rats were fed a standard diet for the total 8 weeks. The present study was approved by the Clinical Research and Experimental Animal Ethics Committee of the First Affiliated Hospital of China Medical University (Shenyang, China). In the trigonelline group, rats were received oral administration of 40 mg/kg/day of trigonelline (Sigma-Aldrich; Merck KGaA) for 8-weeks.

Histopathological analysis of animals. Following the administration of 35 mg/kg pentobarbital sodium (IV), rats were sacrificed by decapitation and the kidneys were collected. Samples were then washed with phosphate-buffered saline (PBS) and fixed in 10% neutral-buffered formalin for 24 h at room temperature. Kidney samples were processed using a routine paraffin embedding technique and 5-μm sections were prepared and stained with hematoxylin and eosin at room temperature for 15 min. Sections were observed using an inverted fluorescence microscope (magnification, x100; Zeiss Axio Observer A1; Carl Zeiss AG, Oberkochen, Germany).

ELISA assay. Blood urea nitrogen (BUN; cat. no. C013-2), creatinine, albumin, interleukin (IL)-1β (cat. no. H002), IL-6 (cat. no. H007), IL-10 (cat. no. H009), IL-18 (cat. no. H015), malondialdehyde (MDA; cat. no. A003-1), superoxide dismutase (SOD; cat. no. A001-1), glutathione (GSH; cat. no. A006-2) and glutathione peroxidase (GSH-Px; cat. no. A005) levels were measured using ELISA kits (all from Nanjing Jiancheng Bioengineering Institute, Nanjing, China) following treatment with trigonelline. Caspase-3/9 levels were measured using Caspase-3/9 levels kits (cat. nos. C1116 and C1158, respectively; Beyotime Institute of Biotechnology, Haimen, China).

Western blot analysis. A total of 50 mg of kidney tissue samples was collected, washed with PBS and homogenized with radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology) for 30 min at 4°C. Samples were centrifuged at 8,000 x g for 10 min at 4°C and the protein concentrations in the supernatants were quantified using a BCA assay. A total of 50 μg of total protein was separated by 10% SDS-PAGE electrophoresis and then transferred to nitro-cellulose membranes. Membranes were blocked with 5% non-fat milk for 1 h at 37°C and probed with Bax (cat. no. 5023; 1:2,000), p53 (cat. no. 2527; 1:2,000), glucose transporter 4 (GLUT4) (cat. no. 2213; 1:1,000), PPAR-γ (cat. no. 2443; 1:1,000), leptin (cat. no. 12497; 1:1,000), tumor necrosis factor (TNF)-α (cat. no. 11948; 1:1,000) and GAPDH antibodies (cat. no. 51332; 1:5,000; all Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C overnight. After washing with Tris-buffered saline with Tween-20 for 15-20 min, membranes were probed with secondary antibody labeled with horseradish peroxidase (7074, 7076, 1:5,000; Cell Signaling Technology, Inc.) for 1 h at 37°C. The protein bands were detected using enhanced chemiluminescent substrate (cat. no. P0018A; Beyotime Institute of Biotechnology) and quantified using Image Lab 3.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Statistical analysis. Data were demonstrated as the mean ± standard deviation using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Statistical analysis was performed using the Student's t-test or one-way analysis of variance followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Trigonelline increases body weight, inhibits the kidney weight/body weight ratio and blood glucose levels in T2DM rats. The chemical structure of trigonelline is presented in Fig. 1A. As indicated in Fig. 1B-D, T2DM resulted in significantly reduced body weight, elevated kidney weight/body weight ratio and increased blood glucose compared with the control group. However, oral administration of 40 mg/kg trigonelline in the trigonelline group for 60 days led to significantly increased body weight, suppressed kidney weight/body weight ratio and decreased blood glucose levels compared with T2DM group (Fig. 1B-D).

Trigonelline reduces the levels of BUN, creatinine and albumin in T2DM rats. It was indicated that the glomerulus, BUN, creatinine and albumin levels were increased in T2DM rats in comparison with control rats (Fig. 2). However, treatment with trigonelline recovered the glomerulus and reduced the levels of BUN, creatinine and albumin in T2DM rats (Fig. 2).

Trigonelline reduces inflammation in T2DM rats. Results indicated significantly increased levels of IL-1β, IL-6 and IL-18 but suppressed IL-10 levels in T2DM rats compared with control rats (Fig. 3). However, trigonelline treatment resulted in significantly decreased levels of IL-1β, IL-6 and IL-18 but increased IL-10 levels in T2DM rats (Fig. 3).

Trigonelline reduces oxidative stress in T2DM rats. Further analysis indicated significantly increased MDA levels, decreased levels of SOD, GSH and GSH-Px in T2DM rats compared with control rats (Fig. 4). Trigonelline administration significantly reduced MDA levels and promoted SOD, GSH and GSH-Px levels in T2DM rats (Fig. 4).

Trigonelline reduces cell apoptosis in T2DM rats. In order to investigate the mechanism of trigonelline in T2DM rats, the protein expression levels of Bax and p53 and the activity levels of caspase-3 and caspase-9 were analyzed. As indicated in Fig. 5, the protein expression levels of p53 and...
Figure 1. Trigonelline increases the body weight, inhibits the kidney weight/body weight ratio and blood glucose levels in T2DM rats. The chemical structure of (A) trigonelline, (B) body weight, (C) kidney weight/body weight ratio and (D) blood glucose were indicated. **P<0.01 vs. control group; ##P<0.01 vs. T2DM group. T2DM, type 2 diabetes.

Figure 2. Trigonelline reduces BUN, creatinine and albumin in T2DM rats. (A) Hematoxylin and eosin staining, (B) BUN, (C) creatinine and (D) albumin levels were indicated. **P<0.01 vs. control group; ##P<0.01 vs. T2DM group. T2DM, type 2 diabetes; BUN, blood urea nitrogen.

Figure 3. Trigonelline reduces inflammation in T2DM rats. (A) IL-1β, (B) IL-6, (C) IL-18 and (D) IL-10 were indicated. **P<0.01 vs. control group; ##P<0.01 vs. T2DM group. T2DM, type 2 diabetes; IL, interleukin.
Bax and the activity levels of caspase-3 and caspase-9 were significantly increased in T2DM rats compared with control rats. Conversely, trigonelline administration significantly suppressed the protein expression levels of p53 and Bax and reduced the activity levels of caspase-3 and caspase-9 in T2DM rats (Fig. 5).

**Discussion**

Diabetes is a metabolic disease that severely threatens human health. It can involve the whole body, leading to lesions in all organs, including the retina and kidneys (11). In recent years, changes in lifestyle have been witnessed (11). Consequently, the morbidity of T2DM characterized by insulin resistance is surging (11). DN has become the most common cause of ESRD in developed countries, including Japan and European and American countries (12). The results of the present study demonstrated that trigonelline significantly increased the body weight but decreased the kidney weight/body weight ratio and blood glucose levels in T2DM rats.

Various studies suggest that insulin resistance serves a vital role in the pathogenesis of diabetes (13,14). The role of local insulin resistance at a cellular level in target organ damage has received increased attention (13). Apart from classical insulin reactive cells, including adipocytes, skeletal...
muscle cells and hepatocytes (13), responses of cardiomyocytes, vascular endothelial cells and other types of cells in the kidney to insulin, as well as their influence, have become research hotspots (14). Notably, T2DM has also been indicated to be a chronic inflammatory disease (14). Numerous inflammatory factors, including cytokines and adhesion factors, directly participate in the development of insulin resistance and diabetic complications (14). Therefore, determining the effect and interaction mechanism of the two in DN damage is of importance to clinical work. Additionally, studying the possible mechanism of suppressing chronic inflammation to improve insulin resistance and relieve renal damage is also of important scientific and clinical value (14). The results of the present study suggested that trigonelline significantly reduced BUN, creatinine and albumin levels, indicating reduced inflammation in T2DM rats. Furthermore, Chowdhury et al (15) demonstrated that trigonelline protects against oxidative stress and proinflammatory cytokines in lipopolysaccharide-induced cognitive impairment in adult mice.

The high glucose status in diabetics typically induces glucose metabolic disorders, which results in the mass production of reactive oxygen species (ROS) (16). In this way, ROS can promote cross-linking polymerization of protein and nucleic acid. SOD, GSH and GSH-PX are important antioxidants, which can effectively eliminate ROS from the body to maintain the balance between oxidation and anti-oxidation (17). Thus, they can protect the cell from damage (16,17). In the present study, it was demonstrated that trigonelline reduced oxidative stress and cell apoptosis in T2DM rats. Notably, Afifi et al (18) concluded that trigonelline attenuates oxidative stress biomarkers in high-fat, high-fructose diet-induced insulin resistance in rats.

Previous studies have demonstrated that PPAR-γ and GLUT4 protein expression levels were downregulated at the time of diabetes (19). Additionally, upregulated PPAR-γ and GLUT4 protein expression levels are associated with protective effects against DN (20). GLUT4 is a transmembrane transport protein that promotes glucose transport to insulin-sensitive tissues for intracellular utilization (19). In this way, it can maintain normal physiological function of cells. PPAR-γ is a type of ligand-activated nuclear transcription factor (21) that is associated with fat differentiation, obesity and insulin resistance (22). Furthermore, PPAR-γ is the target molecule of euglycemic agents, such as thiazolidinediones (22). The results of the present study indicated that trigonelline increased GLUT4 and PPARγ protein expression levels in T2DM rats. Tharaheswari et al (9) suggested that trigonelline and diosgenin attenuated endoplasmic reticulum stress, oxidative stress-mediated damage and PPAR-γ activity in T2DM rats. T2DM, type 2 diabetes; PPAR-γ, peroxisome proliferator-activated receptor-γ; GLUT4, glucose transporter 4; TNF-α, tumor necrosis factor-α.
Participates in regulating the synthesis and secretion of multiple inflammatory mediators (24). Particularly, PPAR-γ serves a vital role in adipocyte differentiation, glucolipid metabolism and insulin resistance (24). PPAR-γ is a class of ligand-activated nuclear transcription factor that can regulate the expression of multiple key genes during glucose and lipid metabolism (25). Notably, leptin is involved in regulating glucose and lipid metabolism in the liver (25). Consequently, leptin may enhance the synthesis of triglycerides and reduce the production of hepatic glycogen (26). A previous study indicated that adipocytes can secrete multiple lipid cytokines and protein factors, among which, leptin, adiponectin, TNF-α and IL-6 are well-known (27). These components have been demonstrated to regulate the biological effect of insulin in target tissues by means of endocrine, paracrine and autocrine signaling (23). Importantly, they may serve critical roles in DN (28). TNF-α is a multi-functional inflammatory cytokine that has been associated with insulin levels, glucose metabolism and lipid metabolism (29). Furthermore, overexpression of TNF-α has been indicated in the lipid tissue of obese individuals (29). Notably, TNF-α acts on the peripheral target tissue and liver after it is released into the blood and thereby induces DN (29). Leptin is the product of the obese gene, which is a hormone secreted by adipocytes and released into blood (27). Research has indicated that there is a two-way regulation between leptin and insulin (27). In the present study, the results indicated that trigonelline suppressed leptin/TNF-α protein expression in T2DM rats. Zhou et al (8) suggested that trigonelline inhibits inflammation and protects β cells to prevent fetal growth restriction during pregnancy through leptin and insulin in diabetes. Antonisamy et al (7) revealed that trigonelline protected against indomethacin-induced gastric ulcers in rats through TNF-α. The present study suggested that trigonelline may regulate leptin/TNF-α to suppress insulin levels in T2DM rats.

In conclusion, the present study demonstrated that trigonelline increased the body weight, inhibited kidney weight/body weight ratio and blood glucose levels in T2DM rats. In addition, it was indicated that trigonelline may be associated with antioxidative, anti-inflammatory and anti-apoptotic mechanisms. The present findings suggest that trigonelline may reduce DN and insulin resistance in T2DM rats through a PPAR-γ/GLUT4-leptin/TNF-α signaling pathway (Fig. 7).

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Authors’ contributions
QiL designed the experiments; YL, QaL, CW and ZL performed the experiments; QiL analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The present study was approved by the Clinical Research and Experimental Animal Ethics Committee of the First Affiliated Hospital of China Medical University (Shenyang, China).
Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


